SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BDR who wrote (1885)3/2/1999 11:42:00 PM
From: rkrw  Read Replies (1) of 10280
 
I trust you know that a generic drug will not be substitutable for an ICE drug until the actual ICE generic is approved. Ala generic Prozac will not be substitutable for ICE Prozac.

Further, for ICE drugs that reach the market before the parent goes generic, I expect the pricing will be at a discount to parent in order to quickly convert the market. I expect SGP will showcase this strategy.
Most HMO's simply have a higher co-pay for patented drugs as a lure to use generic, yet their formularies are fairly liberal as to which drugs they'll cover, all in my experience. If the ICE drug shows improvements in clinical trials in efficacy and safety, I don't see HMO coverage as being an issue. Its a non issue for ICE drugs that are approved prior to parent generic competition. As big pharma catches on to the strategy I expect this will be the case more and more.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News